Seqens Seqens

X

Digital content for Hugel

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Hugel
korearepublicofnew Flag
Country
Country
South Korea
Address
Address
61-20, Sinbuk-ro, Sinbuk-eup, Chuncheon-si, Gangwon-do 24206
Telephone
Telephone
02-6966-1600 / 02-6966-1601
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

https://www.prnewswire.com/news-releases/hugel-receives-fda-approval-in-the-united-states-of-letybo-letibotulinumtoxina-wlbg-for-injection-for-the-treatment-of-glabellar-lines-302078434.html

PR NEWSWIRE
04 Mar 2024

https://www.prnewswire.com/news-releases/hugel-receives-us-fda-approval-for-its-botulinum-toxin-letybo-302077919.html

PR NEWSWIRE
03 Mar 2024

https://www.prnewswire.com/news-releases/hugels-letybo-first-in-korea-to-obtain-marketing-approval-from-australia-301686683.html

PRNEWSWIRE
24 Nov 2022

http://www.pharmabiz.com/NewsDetails.aspx?aid=153706&sid=2

PHARMABIZ
08 Oct 2022

http://www.hugel.co.kr/en/board/board.php?bo_table=press_en&idx=65

PRESS RELEASE
10 Aug 2022

http://www.hugel.co.kr/en/board/board.php?bo_table=press_en&idx=64

PRESS RELEASE
26 Jul 2022

http://www.hugel.co.kr/en/board/board.php?bo_table=press_en&idx=61

PRESS RELEASE
19 May 2022

https://www.pharmacompass.com/pdf/news/fda-issues-form-483-to-hugel-inc-1662529212.pdf

FDA
20 Aug 2021

https://www.prnewswire.com/news-releases/hugel-america-inc-announces-us-fda-acceptance-of-biologics-license-application-bla-for-letibotulinumtoxina-for-injection-to-treat-glabellar-frown-lines-301312900.html

PRNEWSWIRE
15 Jun 2021
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY